Comparative outcomes of reduced intensity and myeloablative allogeneic hematopoietic stem cell transplantation in patients under 50 with hematologic malignancies

被引:2
作者
Kim, Inho
Yoon, Sung Soo
Lee, Kyung-Hun
Keam, Bhumsuk
Kim, Tae Min
Kim, Jin-Soo
Kim, Hoon-Gu
Oh, Myoung-Don
Han, Kyou-Sup
Park, Myoung Hee
Park, Seonyang
Kim, Byoung Kook
机构
[1] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 110744, South Korea
[2] Seoul Natl Univ, Coll Med, Dept Lab Med, Seoul 110744, South Korea
关键词
allogeneic stem cell transplantation; hematological malignancy; reduced intensity conditioning; youths;
D O I
10.1111/j.1399-0012.2006.00512.x
中图分类号
R61 [外科手术学];
学科分类号
摘要
We have conducted a direct comparison of the outcomes of reduced intensity and myeloablative conditioning in younger adults with hematological malignancies < 50 yr. One hundred and five patients received transplants from human leukocyte antigen (HLA)-matched donors, via either reduced intensity (n = 35) or myeloablative conditioning (n = 70). The median ages of the reduced intensity and myeloablative groups were 36 and 33 yr (p = 0.014). Neutrophil engraftment (i.e. time to absolute neutrophil count > 0.5 x 10(9)/L) occurred more rapidly in the reduced intensity group (median: 10 d; range: 0-21 d) than in the myeloablative group (median: 18 d; range: 11-38 d; p < 0.0001). The incidence of grades 2-4 acute graft-vs.-host disease were similar between the reduced intensity and myeloablative groups, at 17% vs. 24% respectively (p = 0.40). The cumulative incidence of day 100 non-relapse mortality was 18% in the reduced intensity group, and 21% in the myeloablative group (p = 0.88). The overall two-yr survival rates were 43% in the reduced intensity group, and 35% in the myeloablative group (p = 0.72). In conclusion, reduced intensity transplantation yielded outcomes comparable with those of myeloablative transplantation in patients under 50 with hematological malignancies.
引用
收藏
页码:496 / 503
页数:8
相关论文
共 22 条
  • [1] Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age
    Alyea, EP
    Kim, HT
    Ho, V
    Cutler, C
    Gribben, J
    DeAngelo, DJ
    Lee, SJ
    Windawi, S
    Ritz, J
    Stone, RM
    Antin, JH
    Soiffer, RJ
    [J]. BLOOD, 2005, 105 (04) : 1810 - 1814
  • [2] A NEW METHOD OF CLASSIFYING PROGNOSTIC CO-MORBIDITY IN LONGITUDINAL-STUDIES - DEVELOPMENT AND VALIDATION
    CHARLSON, ME
    POMPEI, P
    ALES, KL
    MACKENZIE, CR
    [J]. JOURNAL OF CHRONIC DISEASES, 1987, 40 (05): : 373 - 383
  • [3] Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors
    Diaconescu, R
    Flowers, CR
    Storer, B
    Sorror, ML
    Maris, MB
    Maloney, DG
    Sandmaier, BM
    Storb, R
    [J]. BLOOD, 2004, 104 (05) : 1550 - 1558
  • [4] ESSELL JH, 1992, BLOOD, V79, P2784
  • [5] HOW DOES BONE-MARROW TRANSPLANTATION CURE LEUKEMIA
    GALE, RP
    CHAMPLIN, RE
    [J]. LANCET, 1984, 2 (8393) : 28 - 30
  • [6] Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy
    Giralt, S
    Estey, E
    Albitar, M
    vanBesien, K
    Rondon, G
    Anderlini, P
    OBrien, S
    Khouri, I
    Gajewski, J
    Mehra, R
    Claxton, D
    Andersson, B
    Beran, M
    Przepiorka, D
    Koller, C
    Kornblau, S
    Korbling, M
    Keating, M
    Kantarjian, H
    Champlin, R
    [J]. BLOOD, 1997, 89 (12) : 4531 - 4536
  • [7] Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation
    Giralt, S
    Thall, PF
    Khouri, I
    Wang, XM
    Braunschweig, I
    Ippolitti, C
    Claxton, D
    Donato, M
    Bruton, J
    Cohen, A
    Davis, M
    Andersson, BS
    Anderlini, P
    Gajewski, J
    Kornblau, S
    Andreeff, M
    Przepiorka, D
    Ueno, NT
    Molldrem, J
    Champlin, R
    [J]. BLOOD, 2001, 97 (03) : 631 - 637
  • [8] Value of the pretransplant evaluation in predicting toxic day-100 mortality among blood stem-cell and bone marrow transplant recipients
    Goldberg, SL
    Klumpp, TR
    Magdalinski, AJ
    Mangan, KF
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (12) : 3796 - 3802
  • [9] Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients
    Hogan, WJ
    Maris, M
    Storer, B
    Sandmaier, BM
    Maloney, DG
    Schoch, HG
    Woolfrey, AE
    Shulman, HM
    Storb, R
    McDonald, GB
    [J]. BLOOD, 2004, 103 (01) : 78 - 84
  • [10] Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: A matched control study
    Junghanss, C
    Marr, KA
    Carter, RA
    Sandmaier, BM
    Maris, MB
    Maloney, DG
    Chauncey, T
    McSweeney, PA
    Storb, R
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2002, 8 (09) : 512 - 520